Randomized, double-blind, placebo-controlled, multicenter trial (ECHO) Previously untreated Mantle Cell Lymphoma (MCL) who were ineligible for transplant (N=598) Acalabrutinib + R-

6 Dec

Non-Small Cell Lung CancerPancreatic Cancer

New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer

Multi-center, open lavel study (eNRGy) NRG1 fusion positive NSCLC (n=64) and pancreatic adenocarcinoma (n=30) with disease progression after standard therapy

11 Nov

GastroEsophageal Cancer

New Drug: Zolbetuximab with FOLFOX for Gastric and GE Junction Cancer

Phase 3, multicenter, randomized, double-blind trial (SPOTLIGHT) Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, CLDN18.2-positive,

30 Sep

Non-Small Cell Lung Cancer

New Indication: Osimertinib after Chemoradiotherapy in NSCLC

Phase 3, double-blind, placebo-controlled trial (LAURA) Locally advanced, unresectable stage III NSCLC with EGFR exon 19 deletion or L858R mutation after chemoradiation Osimertinib

27 Aug

Non-Small Cell Lung Cancer

New Drug: Lazertinib for EGFR mutated NSCLC

Type: Phase 3, international, randomized trial Population: Patients with previously untreated EGFR-mutated advanced NSCLC (Ex19del or L858R) Treatment: Amivantamab–lazertinib vs.

24 Jun

Small Cell Lung Cancer

New Drug: Tarlatamab for SCLC

Phase 2, open-label (DeLLphi-301) Relapsed/refractory to platinum-based therapy Advanced SCLC Tarlatamamab 10 or 100 mg => Final dose selected as 10 mg

22 Jun

Mesothelioma

New Reference: Pembrolizumab with CISplatin and PEMEtrexed in Mesothelioma

J Clin Oncol 2023 41:17_suppl, LBA8505 Chu QS IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleur

20 Nov

Multiple Myeloma

New Reference: Daratumumab with Lenalidomide and Bortezomib in 1st Line Multiple Myeloma

Lancet Haematol 2023 Oct;10(10):e825-e837 Voorhees PM Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagno

13 Jan

Non-Small Cell Lung Cancer

New Drug: Amivantamab for NSCLC

Phase 3, international, randomized trial (PAPILLON) Advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy Amivantamab + Chemoterapy (n=153) vs.

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries